nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0866	0.121	CbGbCtD
Vismodegib—ABCG2—Dactinomycin—uterine cancer	0.0854	0.119	CbGbCtD
Vismodegib—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0604	0.0843	CbGbCtD
Vismodegib—ABCG2—Carboplatin—uterine cancer	0.0574	0.0801	CbGbCtD
Vismodegib—CYP2C8—Progesterone—uterine cancer	0.0574	0.08	CbGbCtD
Vismodegib—ABCG2—Etoposide—uterine cancer	0.0482	0.0672	CbGbCtD
Vismodegib—CYP2C19—Progesterone—uterine cancer	0.0481	0.0671	CbGbCtD
Vismodegib—CYP2C9—Progesterone—uterine cancer	0.04	0.0558	CbGbCtD
Vismodegib—ABCB1—Progesterone—uterine cancer	0.0388	0.0542	CbGbCtD
Vismodegib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0351	0.049	CbGbCtD
Vismodegib—ABCG2—Doxorubicin—uterine cancer	0.0329	0.0458	CbGbCtD
Vismodegib—ABCB1—Dactinomycin—uterine cancer	0.0308	0.043	CbGbCtD
Vismodegib—CYP2C8—Etoposide—uterine cancer	0.0257	0.0358	CbGbCtD
Vismodegib—CYP3A4—Progesterone—uterine cancer	0.0233	0.0325	CbGbCtD
Vismodegib—ABCB1—Etoposide—uterine cancer	0.0174	0.0242	CbGbCtD
Vismodegib—ABCB1—Doxorubicin—uterine cancer	0.0119	0.0165	CbGbCtD
Vismodegib—CYP3A4—Etoposide—uterine cancer	0.0104	0.0145	CbGbCtD
Vismodegib—CYP3A4—Doxorubicin—uterine cancer	0.0071	0.00991	CbGbCtD
Vismodegib—Musculoskeletal disorder—Progesterone—uterine cancer	0.00598	0.0517	CcSEcCtD
Vismodegib—SHH—epithelium—uterine cancer	0.00539	0.0776	CbGeAlD
Vismodegib—SHH—renal system—uterine cancer	0.005	0.072	CbGeAlD
Vismodegib—SHH—endometrium—uterine cancer	0.00483	0.0696	CbGeAlD
Vismodegib—SMO—myometrium—uterine cancer	0.0048	0.0691	CbGeAlD
Vismodegib—SHH—female reproductive system—uterine cancer	0.004	0.0576	CbGeAlD
Vismodegib—SMO—uterine cervix—uterine cancer	0.00373	0.0538	CbGeAlD
Vismodegib—SMO—endometrium—uterine cancer	0.00338	0.0487	CbGeAlD
Vismodegib—SMO—mammalian vulva—uterine cancer	0.00327	0.0471	CbGeAlD
Vismodegib—SMO—uterus—uterine cancer	0.00311	0.0448	CbGeAlD
Vismodegib—SMO—female reproductive system—uterine cancer	0.0028	0.0403	CbGeAlD
Vismodegib—SMO—female gonad—uterine cancer	0.00255	0.0367	CbGeAlD
Vismodegib—SMO—vagina—uterine cancer	0.00253	0.0365	CbGeAlD
Vismodegib—Neoplasm malignant—Progesterone—uterine cancer	0.0025	0.0216	CcSEcCtD
Vismodegib—Amenorrhoea—Progesterone—uterine cancer	0.00243	0.021	CcSEcCtD
Vismodegib—Neoplasm malignant—Medroxyprogesterone Acetate—uterine cancer	0.00227	0.0196	CcSEcCtD
Vismodegib—Hepatic enzyme increased—Progesterone—uterine cancer	0.00226	0.0195	CcSEcCtD
Vismodegib—Amenorrhoea—Medroxyprogesterone Acetate—uterine cancer	0.0022	0.0191	CcSEcCtD
Vismodegib—Musculoskeletal pain—Progesterone—uterine cancer	0.00216	0.0187	CcSEcCtD
Vismodegib—Musculoskeletal pain—Medroxyprogesterone Acetate—uterine cancer	0.00196	0.0169	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Medroxyprogesterone Acetate—uterine cancer	0.00194	0.0167	CcSEcCtD
Vismodegib—SMO—lymph node—uterine cancer	0.00164	0.0236	CbGeAlD
Vismodegib—Blood alkaline phosphatase increased—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.014	CcSEcCtD
Vismodegib—Musculoskeletal chest pain—Epirubicin—uterine cancer	0.00158	0.0137	CcSEcCtD
Vismodegib—Pain in extremity—Progesterone—uterine cancer	0.00155	0.0134	CcSEcCtD
Vismodegib—ORM1—endometrium—uterine cancer	0.00148	0.0213	CbGeAlD
Vismodegib—Musculoskeletal chest pain—Doxorubicin—uterine cancer	0.00146	0.0126	CcSEcCtD
Vismodegib—Pain in extremity—Medroxyprogesterone Acetate—uterine cancer	0.00141	0.0122	CcSEcCtD
Vismodegib—Breast disorder—Progesterone—uterine cancer	0.0014	0.0121	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Progesterone—uterine cancer	0.0014	0.0121	CcSEcCtD
Vismodegib—Hypokalaemia—Medroxyprogesterone Acetate—uterine cancer	0.00128	0.0111	CcSEcCtD
Vismodegib—Breast disorder—Medroxyprogesterone Acetate—uterine cancer	0.00127	0.011	CcSEcCtD
Vismodegib—ABCG2—myometrium—uterine cancer	0.00126	0.0181	CbGeAlD
Vismodegib—Pain—Carboplatin—uterine cancer	0.00124	0.0107	CcSEcCtD
Vismodegib—ORM1—female reproductive system—uterine cancer	0.00122	0.0176	CbGeAlD
Vismodegib—Weight decreased—Progesterone—uterine cancer	0.00121	0.0105	CcSEcCtD
Vismodegib—Weight decreased—Medroxyprogesterone Acetate—uterine cancer	0.0011	0.0095	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Etoposide—uterine cancer	0.00109	0.00945	CcSEcCtD
Vismodegib—Connective tissue disorder—Progesterone—uterine cancer	0.00105	0.00912	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Dactinomycin—uterine cancer	0.000987	0.00854	CcSEcCtD
Vismodegib—ABCG2—uterine cervix—uterine cancer	0.000978	0.0141	CbGeAlD
Vismodegib—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.000955	0.00826	CcSEcCtD
Vismodegib—Alopecia—Progesterone—uterine cancer	0.000948	0.0082	CcSEcCtD
Vismodegib—CYP2C8—renal system—uterine cancer	0.000941	0.0136	CbGeAlD
Vismodegib—Malnutrition—Progesterone—uterine cancer	0.000934	0.00808	CcSEcCtD
Vismodegib—ABCG2—decidua—uterine cancer	0.000932	0.0134	CbGeAlD
Vismodegib—Blood alkaline phosphatase increased—Etoposide—uterine cancer	0.000912	0.00789	CcSEcCtD
Vismodegib—CYP2C8—endometrium—uterine cancer	0.00091	0.0131	CbGeAlD
Vismodegib—Back pain—Progesterone—uterine cancer	0.000903	0.00781	CcSEcCtD
Vismodegib—Muscle spasms—Progesterone—uterine cancer	0.000898	0.00777	CcSEcCtD
Vismodegib—ABCG2—endometrium—uterine cancer	0.000885	0.0127	CbGeAlD
Vismodegib—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.000859	0.00743	CcSEcCtD
Vismodegib—ABCG2—mammalian vulva—uterine cancer	0.000856	0.0123	CbGeAlD
Vismodegib—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.000846	0.00732	CcSEcCtD
Vismodegib—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.000829	0.00717	CcSEcCtD
Vismodegib—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.000819	0.00708	CcSEcCtD
Vismodegib—ABCG2—uterus—uterine cancer	0.000815	0.0117	CbGeAlD
Vismodegib—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.000814	0.00704	CcSEcCtD
Vismodegib—Myalgia—Progesterone—uterine cancer	0.000795	0.00688	CcSEcCtD
Vismodegib—Arthralgia—Progesterone—uterine cancer	0.000795	0.00688	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00079	0.00683	CcSEcCtD
Vismodegib—CYP2C19—vagina—uterine cancer	0.000781	0.0113	CbGeAlD
Vismodegib—Ageusia—Epirubicin—uterine cancer	0.000756	0.00654	CcSEcCtD
Vismodegib—CYP2C8—female reproductive system—uterine cancer	0.000754	0.0109	CbGeAlD
Vismodegib—Nervous system disorder—Progesterone—uterine cancer	0.000747	0.00647	CcSEcCtD
Vismodegib—Skin disorder—Progesterone—uterine cancer	0.00074	0.0064	CcSEcCtD
Vismodegib—Myalgia—Medroxyprogesterone Acetate—uterine cancer	0.00072	0.00623	CcSEcCtD
Vismodegib—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.00072	0.00623	CcSEcCtD
Vismodegib—Neoplasm malignant—Epirubicin—uterine cancer	0.000717	0.00621	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000715	0.00619	CcSEcCtD
Vismodegib—ORM1—lymph node—uterine cancer	0.000715	0.0103	CbGeAlD
Vismodegib—Ageusia—Doxorubicin—uterine cancer	0.0007	0.00605	CcSEcCtD
Vismodegib—Amenorrhoea—Epirubicin—uterine cancer	0.000697	0.00603	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Progesterone—uterine cancer	0.000694	0.00601	CcSEcCtD
Vismodegib—CYP2C8—vagina—uterine cancer	0.000682	0.00982	CbGeAlD
Vismodegib—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000677	0.00586	CcSEcCtD
Vismodegib—Dyspepsia—Progesterone—uterine cancer	0.000671	0.0058	CcSEcCtD
Vismodegib—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000671	0.0058	CcSEcCtD
Vismodegib—Alopecia—Dactinomycin—uterine cancer	0.00067	0.0058	CcSEcCtD
Vismodegib—CYP2C9—female reproductive system—uterine cancer	0.000669	0.00964	CbGeAlD
Vismodegib—ABCG2—female gonad—uterine cancer	0.000667	0.00961	CbGeAlD
Vismodegib—Neoplasm malignant—Doxorubicin—uterine cancer	0.000664	0.00574	CcSEcCtD
Vismodegib—ABCG2—vagina—uterine cancer	0.000663	0.00955	CbGeAlD
Vismodegib—Decreased appetite—Progesterone—uterine cancer	0.000663	0.00573	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Progesterone—uterine cancer	0.000658	0.00569	CcSEcCtD
Vismodegib—Fatigue—Progesterone—uterine cancer	0.000657	0.00568	CcSEcCtD
Vismodegib—Pain—Progesterone—uterine cancer	0.000652	0.00564	CcSEcCtD
Vismodegib—Constipation—Progesterone—uterine cancer	0.000652	0.00564	CcSEcCtD
Vismodegib—Amenorrhoea—Doxorubicin—uterine cancer	0.000645	0.00558	CcSEcCtD
Vismodegib—CYP3A4—renal system—uterine cancer	0.000637	0.00918	CbGeAlD
Vismodegib—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000629	0.00544	CcSEcCtD
Vismodegib—ALB—lymph node—uterine cancer	0.000627	0.00904	CbGeAlD
Vismodegib—Gastrointestinal pain—Progesterone—uterine cancer	0.000623	0.00539	CcSEcCtD
Vismodegib—Musculoskeletal pain—Epirubicin—uterine cancer	0.00062	0.00536	CcSEcCtD
Vismodegib—ABCB1—myometrium—uterine cancer	0.00062	0.00893	CbGeAlD
Vismodegib—Phosphatase alkaline increased—Epirubicin—uterine cancer	0.000613	0.0053	CcSEcCtD
Vismodegib—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000608	0.00526	CcSEcCtD
Vismodegib—Abdominal pain—Progesterone—uterine cancer	0.000602	0.00521	CcSEcCtD
Vismodegib—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.0006	0.00519	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000596	0.00516	CcSEcCtD
Vismodegib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000595	0.00515	CcSEcCtD
Vismodegib—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000591	0.00511	CcSEcCtD
Vismodegib—Blood urea increased—Epirubicin—uterine cancer	0.000578	0.005	CcSEcCtD
Vismodegib—Musculoskeletal pain—Doxorubicin—uterine cancer	0.000574	0.00496	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Doxorubicin—uterine cancer	0.000567	0.0049	CcSEcCtD
Vismodegib—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000565	0.00489	CcSEcCtD
Vismodegib—Myalgia—Dactinomycin—uterine cancer	0.000562	0.00486	CcSEcCtD
Vismodegib—Asthenia—Progesterone—uterine cancer	0.000547	0.00473	CcSEcCtD
Vismodegib—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000546	0.00472	CcSEcCtD
Vismodegib—Pruritus—Progesterone—uterine cancer	0.000539	0.00466	CcSEcCtD
Vismodegib—Blood urea increased—Doxorubicin—uterine cancer	0.000535	0.00463	CcSEcCtD
Vismodegib—Diarrhoea—Progesterone—uterine cancer	0.000521	0.00451	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	0.000511	0.00442	CcSEcCtD
Vismodegib—CYP3A4—female reproductive system—uterine cancer	0.00051	0.00735	CbGeAlD
Vismodegib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000496	0.00429	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000491	0.00425	CcSEcCtD
Vismodegib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000489	0.00423	CcSEcCtD
Vismodegib—ABCB1—epithelium—uterine cancer	0.000486	0.00701	CbGeAlD
Vismodegib—Alopecia—Etoposide—uterine cancer	0.000485	0.00419	CcSEcCtD
Vismodegib—Vomiting—Progesterone—uterine cancer	0.000485	0.00419	CcSEcCtD
Vismodegib—ABCB1—uterine cervix—uterine cancer	0.000482	0.00695	CbGeAlD
Vismodegib—Rash—Progesterone—uterine cancer	0.000481	0.00416	CcSEcCtD
Vismodegib—Dermatitis—Progesterone—uterine cancer	0.00048	0.00415	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000473	0.00409	CcSEcCtD
Vismodegib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000473	0.00409	CcSEcCtD
Vismodegib—Decreased appetite—Dactinomycin—uterine cancer	0.000468	0.00405	CcSEcCtD
Vismodegib—Dysgeusia—Etoposide—uterine cancer	0.000468	0.00405	CcSEcCtD
Vismodegib—Fatigue—Dactinomycin—uterine cancer	0.000464	0.00402	CcSEcCtD
Vismodegib—Back pain—Etoposide—uterine cancer	0.000462	0.004	CcSEcCtD
Vismodegib—Pain—Dactinomycin—uterine cancer	0.000461	0.00398	CcSEcCtD
Vismodegib—ABCB1—decidua—uterine cancer	0.000459	0.00662	CbGeAlD
Vismodegib—Muscle spasms—Etoposide—uterine cancer	0.000459	0.00397	CcSEcCtD
Vismodegib—Nausea—Progesterone—uterine cancer	0.000453	0.00392	CcSEcCtD
Vismodegib—ABCB1—renal system—uterine cancer	0.000451	0.0065	CbGeAlD
Vismodegib—Hyponatraemia—Epirubicin—uterine cancer	0.000446	0.00386	CcSEcCtD
Vismodegib—Pain in extremity—Epirubicin—uterine cancer	0.000445	0.00385	CcSEcCtD
Vismodegib—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000441	0.00381	CcSEcCtD
Vismodegib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000439	0.0038	CcSEcCtD
Vismodegib—ABCB1—endometrium—uterine cancer	0.000436	0.00628	CbGeAlD
Vismodegib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000435	0.00377	CcSEcCtD
Vismodegib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000435	0.00376	CcSEcCtD
Vismodegib—ABCG2—lymph node—uterine cancer	0.000429	0.00618	CbGeAlD
Vismodegib—Abdominal pain—Dactinomycin—uterine cancer	0.000426	0.00368	CcSEcCtD
Vismodegib—ABCB1—mammalian vulva—uterine cancer	0.000422	0.00608	CbGeAlD
Vismodegib—Dehydration—Epirubicin—uterine cancer	0.000414	0.00358	CcSEcCtD
Vismodegib—Hyponatraemia—Doxorubicin—uterine cancer	0.000413	0.00357	CcSEcCtD
Vismodegib—Pain in extremity—Doxorubicin—uterine cancer	0.000411	0.00356	CcSEcCtD
Vismodegib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00041	0.00355	CcSEcCtD
Vismodegib—Abdominal pain upper—Epirubicin—uterine cancer	0.000406	0.00351	CcSEcCtD
Vismodegib—Hypokalaemia—Epirubicin—uterine cancer	0.000405	0.0035	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000404	0.00349	CcSEcCtD
Vismodegib—ABCB1—uterus—uterine cancer	0.000402	0.00579	CbGeAlD
Vismodegib—Breast disorder—Epirubicin—uterine cancer	0.000402	0.00348	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.0004	0.00346	CcSEcCtD
Vismodegib—Asthenia—Dactinomycin—uterine cancer	0.000387	0.00334	CcSEcCtD
Vismodegib—Dehydration—Doxorubicin—uterine cancer	0.000383	0.00331	CcSEcCtD
Vismodegib—Skin disorder—Etoposide—uterine cancer	0.000379	0.00328	CcSEcCtD
Vismodegib—Abdominal pain upper—Doxorubicin—uterine cancer	0.000376	0.00325	CcSEcCtD
Vismodegib—Hypokalaemia—Doxorubicin—uterine cancer	0.000374	0.00324	CcSEcCtD
Vismodegib—Breast disorder—Doxorubicin—uterine cancer	0.000372	0.00322	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.00037	0.0032	CcSEcCtD
Vismodegib—Diarrhoea—Dactinomycin—uterine cancer	0.000369	0.00319	CcSEcCtD
Vismodegib—ABCB1—female reproductive system—uterine cancer	0.000361	0.00521	CbGeAlD
Vismodegib—Weight decreased—Epirubicin—uterine cancer	0.000348	0.00301	CcSEcCtD
Vismodegib—Vomiting—Dactinomycin—uterine cancer	0.000343	0.00296	CcSEcCtD
Vismodegib—Rash—Dactinomycin—uterine cancer	0.00034	0.00294	CcSEcCtD
Vismodegib—Decreased appetite—Etoposide—uterine cancer	0.000339	0.00293	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000337	0.00291	CcSEcCtD
Vismodegib—Fatigue—Etoposide—uterine cancer	0.000336	0.00291	CcSEcCtD
Vismodegib—Constipation—Etoposide—uterine cancer	0.000333	0.00288	CcSEcCtD
Vismodegib—Pain—Etoposide—uterine cancer	0.000333	0.00288	CcSEcCtD
Vismodegib—ABCB1—female gonad—uterine cancer	0.000329	0.00474	CbGeAlD
Vismodegib—ABCB1—vagina—uterine cancer	0.000327	0.00471	CbGeAlD
Vismodegib—Weight decreased—Doxorubicin—uterine cancer	0.000322	0.00278	CcSEcCtD
Vismodegib—Nausea—Dactinomycin—uterine cancer	0.00032	0.00277	CcSEcCtD
Vismodegib—Gastrointestinal pain—Etoposide—uterine cancer	0.000319	0.00276	CcSEcCtD
Vismodegib—Abdominal pain—Etoposide—uterine cancer	0.000308	0.00267	CcSEcCtD
Vismodegib—Connective tissue disorder—Epirubicin—uterine cancer	0.000302	0.00261	CcSEcCtD
Vismodegib—Asthenia—Etoposide—uterine cancer	0.00028	0.00242	CcSEcCtD
Vismodegib—Connective tissue disorder—Doxorubicin—uterine cancer	0.00028	0.00242	CcSEcCtD
Vismodegib—Pruritus—Etoposide—uterine cancer	0.000276	0.00239	CcSEcCtD
Vismodegib—Alopecia—Epirubicin—uterine cancer	0.000272	0.00235	CcSEcCtD
Vismodegib—Malnutrition—Epirubicin—uterine cancer	0.000268	0.00232	CcSEcCtD
Vismodegib—Diarrhoea—Etoposide—uterine cancer	0.000267	0.00231	CcSEcCtD
Vismodegib—Dysgeusia—Epirubicin—uterine cancer	0.000262	0.00227	CcSEcCtD
Vismodegib—Back pain—Epirubicin—uterine cancer	0.000259	0.00224	CcSEcCtD
Vismodegib—Muscle spasms—Epirubicin—uterine cancer	0.000257	0.00223	CcSEcCtD
Vismodegib—Alopecia—Doxorubicin—uterine cancer	0.000252	0.00218	CcSEcCtD
Vismodegib—Vomiting—Etoposide—uterine cancer	0.000248	0.00214	CcSEcCtD
Vismodegib—Malnutrition—Doxorubicin—uterine cancer	0.000248	0.00214	CcSEcCtD
Vismodegib—Rash—Etoposide—uterine cancer	0.000246	0.00213	CcSEcCtD
Vismodegib—Dermatitis—Etoposide—uterine cancer	0.000246	0.00212	CcSEcCtD
Vismodegib—Dysgeusia—Doxorubicin—uterine cancer	0.000243	0.0021	CcSEcCtD
Vismodegib—Back pain—Doxorubicin—uterine cancer	0.00024	0.00207	CcSEcCtD
Vismodegib—Muscle spasms—Doxorubicin—uterine cancer	0.000238	0.00206	CcSEcCtD
Vismodegib—Nausea—Etoposide—uterine cancer	0.000232	0.002	CcSEcCtD
Vismodegib—Myalgia—Epirubicin—uterine cancer	0.000228	0.00197	CcSEcCtD
Vismodegib—Arthralgia—Epirubicin—uterine cancer	0.000228	0.00197	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000226	0.00196	CcSEcCtD
Vismodegib—Nervous system disorder—Epirubicin—uterine cancer	0.000214	0.00185	CcSEcCtD
Vismodegib—Skin disorder—Epirubicin—uterine cancer	0.000212	0.00184	CcSEcCtD
Vismodegib—ABCB1—lymph node—uterine cancer	0.000211	0.00305	CbGeAlD
Vismodegib—Arthralgia—Doxorubicin—uterine cancer	0.000211	0.00182	CcSEcCtD
Vismodegib—Myalgia—Doxorubicin—uterine cancer	0.000211	0.00182	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000209	0.00181	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000199	0.00172	CcSEcCtD
Vismodegib—Nervous system disorder—Doxorubicin—uterine cancer	0.000198	0.00172	CcSEcCtD
Vismodegib—Skin disorder—Doxorubicin—uterine cancer	0.000196	0.0017	CcSEcCtD
Vismodegib—Dyspepsia—Epirubicin—uterine cancer	0.000192	0.00166	CcSEcCtD
Vismodegib—Decreased appetite—Epirubicin—uterine cancer	0.00019	0.00164	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000189	0.00163	CcSEcCtD
Vismodegib—Fatigue—Epirubicin—uterine cancer	0.000188	0.00163	CcSEcCtD
Vismodegib—Pain—Epirubicin—uterine cancer	0.000187	0.00162	CcSEcCtD
Vismodegib—Constipation—Epirubicin—uterine cancer	0.000187	0.00162	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000184	0.00159	CcSEcCtD
Vismodegib—Gastrointestinal pain—Epirubicin—uterine cancer	0.000179	0.00155	CcSEcCtD
Vismodegib—Dyspepsia—Doxorubicin—uterine cancer	0.000178	0.00154	CcSEcCtD
Vismodegib—Decreased appetite—Doxorubicin—uterine cancer	0.000176	0.00152	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000175	0.00151	CcSEcCtD
Vismodegib—Fatigue—Doxorubicin—uterine cancer	0.000174	0.00151	CcSEcCtD
Vismodegib—Pain—Doxorubicin—uterine cancer	0.000173	0.0015	CcSEcCtD
Vismodegib—Constipation—Doxorubicin—uterine cancer	0.000173	0.0015	CcSEcCtD
Vismodegib—Abdominal pain—Epirubicin—uterine cancer	0.000173	0.00149	CcSEcCtD
Vismodegib—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000165	0.00143	CcSEcCtD
Vismodegib—Abdominal pain—Doxorubicin—uterine cancer	0.00016	0.00138	CcSEcCtD
Vismodegib—Asthenia—Epirubicin—uterine cancer	0.000157	0.00136	CcSEcCtD
Vismodegib—Pruritus—Epirubicin—uterine cancer	0.000155	0.00134	CcSEcCtD
Vismodegib—Diarrhoea—Epirubicin—uterine cancer	0.00015	0.00129	CcSEcCtD
Vismodegib—Asthenia—Doxorubicin—uterine cancer	0.000145	0.00126	CcSEcCtD
Vismodegib—Pruritus—Doxorubicin—uterine cancer	0.000143	0.00124	CcSEcCtD
Vismodegib—Vomiting—Epirubicin—uterine cancer	0.000139	0.0012	CcSEcCtD
Vismodegib—Diarrhoea—Doxorubicin—uterine cancer	0.000138	0.0012	CcSEcCtD
Vismodegib—Rash—Epirubicin—uterine cancer	0.000138	0.00119	CcSEcCtD
Vismodegib—Dermatitis—Epirubicin—uterine cancer	0.000138	0.00119	CcSEcCtD
Vismodegib—Nausea—Epirubicin—uterine cancer	0.00013	0.00112	CcSEcCtD
Vismodegib—Vomiting—Doxorubicin—uterine cancer	0.000129	0.00111	CcSEcCtD
Vismodegib—Rash—Doxorubicin—uterine cancer	0.000128	0.0011	CcSEcCtD
Vismodegib—Dermatitis—Doxorubicin—uterine cancer	0.000127	0.0011	CcSEcCtD
Vismodegib—Nausea—Doxorubicin—uterine cancer	0.00012	0.00104	CcSEcCtD
Vismodegib—SMO—Signaling Pathways—CDKN2B—uterine cancer	7.82e-05	0.000798	CbGpPWpGaD
Vismodegib—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	7.73e-05	0.000789	CbGpPWpGaD
Vismodegib—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	7.63e-05	0.000778	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	7.61e-05	0.000777	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—IGF1R—uterine cancer	7.59e-05	0.000775	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—SMAD3—uterine cancer	7.53e-05	0.000768	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	7.4e-05	0.000755	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	7.4e-05	0.000755	CbGpPWpGaD
Vismodegib—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	7.36e-05	0.000751	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—CXCL8—uterine cancer	7.24e-05	0.000739	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—FGFR2—uterine cancer	7.18e-05	0.000733	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—CXCL8—uterine cancer	7.17e-05	0.000732	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—SMAD3—uterine cancer	7.14e-05	0.000728	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	7.1e-05	0.000725	CbGpPWpGaD
Vismodegib—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	6.93e-05	0.000707	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	6.87e-05	0.000701	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CXCL8—uterine cancer	6.86e-05	0.0007	CbGpPWpGaD
Vismodegib—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	6.84e-05	0.000698	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	6.82e-05	0.000696	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—FGFR2—uterine cancer	6.81e-05	0.000695	CbGpPWpGaD
Vismodegib—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	6.77e-05	0.000691	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	6.75e-05	0.000688	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	6.75e-05	0.000688	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	6.73e-05	0.000686	CbGpPWpGaD
Vismodegib—ALB—Platelet degranulation—VEGFA—uterine cancer	6.58e-05	0.000671	CbGpPWpGaD
Vismodegib—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	6.46e-05	0.000659	CbGpPWpGaD
Vismodegib—SHH—Disease—ERBB2—uterine cancer	6.44e-05	0.000657	CbGpPWpGaD
Vismodegib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	6.27e-05	0.00064	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—ESR1—uterine cancer	6.14e-05	0.000627	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	6.08e-05	0.000621	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	6.05e-05	0.000617	CbGpPWpGaD
Vismodegib—SHH—Disease—CDKN1B—uterine cancer	5.96e-05	0.000609	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AKR1B1—uterine cancer	5.95e-05	0.000607	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—STAR—uterine cancer	5.95e-05	0.000607	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—ESR1—uterine cancer	5.82e-05	0.000594	CbGpPWpGaD
Vismodegib—ABCB1—Allograft Rejection—VEGFA—uterine cancer	5.82e-05	0.000594	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—NRAS—uterine cancer	5.81e-05	0.000593	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—TP53—uterine cancer	5.8e-05	0.000592	CbGpPWpGaD
Vismodegib—SHH—Disease—CTNNB1—uterine cancer	5.63e-05	0.000575	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—NRAS—uterine cancer	5.51e-05	0.000562	CbGpPWpGaD
Vismodegib—SHH—Disease—PTEN—uterine cancer	5.49e-05	0.00056	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	5.43e-05	0.000554	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCL2—uterine cancer	5.41e-05	0.000552	CbGpPWpGaD
Vismodegib—SHH—Disease—EP300—uterine cancer	5.24e-05	0.000534	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCL2—uterine cancer	5.13e-05	0.000523	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NDUFB11—uterine cancer	5.11e-05	0.000521	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—SRD5A2—uterine cancer	5.11e-05	0.000521	CbGpPWpGaD
Vismodegib—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	5.1e-05	0.00052	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IRF1—uterine cancer	5.09e-05	0.000519	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	5.08e-05	0.000519	CbGpPWpGaD
Vismodegib—ALB—Metabolism—SRD5A2—uterine cancer	5.08e-05	0.000518	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NDUFB11—uterine cancer	5.08e-05	0.000518	CbGpPWpGaD
Vismodegib—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	5.03e-05	0.000513	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—KRAS—uterine cancer	5e-05	0.00051	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.96e-05	0.000506	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.95e-05	0.000505	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.93e-05	0.000503	CbGpPWpGaD
Vismodegib—SHH—Disease—NRAS—uterine cancer	4.9e-05	0.0005	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—KRAS—uterine cancer	4.74e-05	0.000484	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.68e-05	0.000478	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—POLD1—uterine cancer	4.67e-05	0.000476	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.66e-05	0.000475	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—PIK3CA—uterine cancer	4.59e-05	0.000469	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—NDUFB11—uterine cancer	4.56e-05	0.000465	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—SRD5A2—uterine cancer	4.56e-05	0.000465	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—ERBB2—uterine cancer	4.51e-05	0.00046	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NDUFB11—uterine cancer	4.45e-05	0.000454	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SRD5A2—uterine cancer	4.45e-05	0.000454	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.43e-05	0.000452	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AKR1C1—uterine cancer	4.37e-05	0.000445	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—PIK3CA—uterine cancer	4.35e-05	0.000444	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	4.29e-05	0.000438	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CXCL8—uterine cancer	4.28e-05	0.000436	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—ERBB2—uterine cancer	4.28e-05	0.000436	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—HRAS—uterine cancer	4.25e-05	0.000434	CbGpPWpGaD
Vismodegib—SHH—Disease—KRAS—uterine cancer	4.22e-05	0.00043	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.18e-05	0.000427	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CDKN1B—uterine cancer	4.18e-05	0.000426	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SRD5A2—uterine cancer	4.16e-05	0.000424	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NDUFB11—uterine cancer	4.16e-05	0.000424	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CXCL8—uterine cancer	4.05e-05	0.000414	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.04e-05	0.000412	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—HRAS—uterine cancer	4.03e-05	0.000411	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CDKN1B—uterine cancer	3.96e-05	0.000404	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CTNNB1—uterine cancer	3.95e-05	0.000403	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—RRM2—uterine cancer	3.89e-05	0.000397	CbGpPWpGaD
Vismodegib—SHH—Disease—PIK3CA—uterine cancer	3.87e-05	0.000395	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PTEN—uterine cancer	3.85e-05	0.000392	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.81e-05	0.000389	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—DCN—uterine cancer	3.78e-05	0.000385	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—AKT1—uterine cancer	3.75e-05	0.000383	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CTNNB1—uterine cancer	3.74e-05	0.000382	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	3.73e-05	0.000381	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AKR1B1—uterine cancer	3.69e-05	0.000377	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—STAR—uterine cancer	3.69e-05	0.000377	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AKR1B1—uterine cancer	3.67e-05	0.000374	CbGpPWpGaD
Vismodegib—ALB—Metabolism—STAR—uterine cancer	3.67e-05	0.000374	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—EP300—uterine cancer	3.67e-05	0.000374	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.65e-05	0.000372	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PTEN—uterine cancer	3.65e-05	0.000372	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.63e-05	0.00037	CbGpPWpGaD
Vismodegib—SHH—Disease—HRAS—uterine cancer	3.58e-05	0.000366	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CYP11A1—uterine cancer	3.56e-05	0.000363	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—AKT1—uterine cancer	3.56e-05	0.000363	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—EP300—uterine cancer	3.48e-05	0.000355	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—VEGFA—uterine cancer	3.47e-05	0.000354	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	3.46e-05	0.000353	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—NRAS—uterine cancer	3.43e-05	0.00035	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AKR1C3—uterine cancer	3.36e-05	0.000343	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—STAR—uterine cancer	3.29e-05	0.000336	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AKR1B1—uterine cancer	3.29e-05	0.000336	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—VEGFA—uterine cancer	3.29e-05	0.000336	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	3.27e-05	0.000333	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.26e-05	0.000332	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—NRAS—uterine cancer	3.25e-05	0.000332	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—STAR—uterine cancer	3.22e-05	0.000328	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AKR1B1—uterine cancer	3.22e-05	0.000328	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	3.18e-05	0.000325	CbGpPWpGaD
Vismodegib—SHH—Disease—AKT1—uterine cancer	3.17e-05	0.000323	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	3.03e-05	0.00031	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—STAR—uterine cancer	3e-05	0.000307	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKR1B1—uterine cancer	3e-05	0.000307	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.97e-05	0.000303	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KRAS—uterine cancer	2.95e-05	0.000301	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	2.92e-05	0.000298	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—POLD1—uterine cancer	2.9e-05	0.000296	CbGpPWpGaD
Vismodegib—ALB—Metabolism—POLD1—uterine cancer	2.88e-05	0.000294	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.87e-05	0.000293	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KRAS—uterine cancer	2.8e-05	0.000286	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SRD5A2—uterine cancer	2.74e-05	0.00028	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NDUFB11—uterine cancer	2.74e-05	0.00028	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PIK3CA—uterine cancer	2.71e-05	0.000277	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AKR1C1—uterine cancer	2.71e-05	0.000276	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AKR1C1—uterine cancer	2.69e-05	0.000275	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TP53—uterine cancer	2.62e-05	0.000268	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—STK11—uterine cancer	2.62e-05	0.000267	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CYP19A1—uterine cancer	2.62e-05	0.000267	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—POLD1—uterine cancer	2.59e-05	0.000264	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PIK3CA—uterine cancer	2.57e-05	0.000262	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—POLD1—uterine cancer	2.52e-05	0.000257	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—HRAS—uterine cancer	2.51e-05	0.000256	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TP53—uterine cancer	2.49e-05	0.000254	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	2.44e-05	0.000249	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AKR1C1—uterine cancer	2.42e-05	0.000247	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—RRM2—uterine cancer	2.41e-05	0.000246	CbGpPWpGaD
Vismodegib—ALB—Metabolism—RRM2—uterine cancer	2.4e-05	0.000245	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—HRAS—uterine cancer	2.38e-05	0.000243	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AKR1C1—uterine cancer	2.36e-05	0.000241	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—POLD1—uterine cancer	2.36e-05	0.000241	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—DCN—uterine cancer	2.34e-05	0.000239	CbGpPWpGaD
Vismodegib—ALB—Metabolism—DCN—uterine cancer	2.33e-05	0.000238	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	2.28e-05	0.000233	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	2.24e-05	0.000229	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—AKT1—uterine cancer	2.22e-05	0.000226	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYP11A1—uterine cancer	2.21e-05	0.000225	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKR1C1—uterine cancer	2.21e-05	0.000225	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYP11A1—uterine cancer	2.2e-05	0.000224	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.17e-05	0.000222	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—RRM2—uterine cancer	2.16e-05	0.00022	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—RRM2—uterine cancer	2.1e-05	0.000215	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—AKT1—uterine cancer	2.1e-05	0.000214	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—DCN—uterine cancer	2.09e-05	0.000214	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AKR1C3—uterine cancer	2.09e-05	0.000213	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AKR1C3—uterine cancer	2.07e-05	0.000212	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—DCN—uterine cancer	2.04e-05	0.000208	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—STAR—uterine cancer	1.98e-05	0.000202	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.98e-05	0.000202	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP11A1—uterine cancer	1.97e-05	0.000201	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—MTHFR—uterine cancer	1.97e-05	0.000201	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—RRM2—uterine cancer	1.97e-05	0.000201	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP11A1—uterine cancer	1.92e-05	0.000196	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—DCN—uterine cancer	1.91e-05	0.000195	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	1.86e-05	0.00019	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AKR1C3—uterine cancer	1.86e-05	0.00019	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.83e-05	0.000187	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AKR1C3—uterine cancer	1.82e-05	0.000185	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.8e-05	0.000183	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.7e-05	0.000173	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—STK11—uterine cancer	1.62e-05	0.000166	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CYP19A1—uterine cancer	1.62e-05	0.000166	CbGpPWpGaD
Vismodegib—ALB—Metabolism—STK11—uterine cancer	1.62e-05	0.000165	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CYP19A1—uterine cancer	1.62e-05	0.000165	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—EP300—uterine cancer	1.59e-05	0.000162	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—POLD1—uterine cancer	1.55e-05	0.000159	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.53e-05	0.000156	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.52e-05	0.000155	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—VEGFA—uterine cancer	1.5e-05	0.000154	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NRAS—uterine cancer	1.49e-05	0.000152	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.45e-05	0.000148	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.45e-05	0.000148	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CYP19A1—uterine cancer	1.45e-05	0.000148	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—STK11—uterine cancer	1.45e-05	0.000148	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.45e-05	0.000148	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—STK11—uterine cancer	1.42e-05	0.000144	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CYP19A1—uterine cancer	1.42e-05	0.000144	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.36e-05	0.000139	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—STK11—uterine cancer	1.32e-05	0.000135	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.32e-05	0.000135	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.3e-05	0.000132	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—RRM2—uterine cancer	1.3e-05	0.000132	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—KRAS—uterine cancer	1.28e-05	0.000131	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—DCN—uterine cancer	1.26e-05	0.000128	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.24e-05	0.000127	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—MTHFR—uterine cancer	1.22e-05	0.000125	CbGpPWpGaD
Vismodegib—ALB—Metabolism—MTHFR—uterine cancer	1.21e-05	0.000124	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.19e-05	0.000121	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.18e-05	0.000121	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PIK3CA—uterine cancer	1.18e-05	0.00012	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—uterine cancer	1.14e-05	0.000116	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.12e-05	0.000114	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTEN—uterine cancer	1.09e-05	0.000112	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—MTHFR—uterine cancer	1.09e-05	0.000111	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—HRAS—uterine cancer	1.09e-05	0.000111	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.08e-05	0.00011	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.07e-05	0.000109	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—MTHFR—uterine cancer	1.06e-05	0.000109	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—EP300—uterine cancer	1.04e-05	0.000107	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—MTHFR—uterine cancer	9.94e-06	0.000101	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	9.6e-06	9.8e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—AKT1—uterine cancer	9.6e-06	9.8e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.76e-06	8.94e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—STK11—uterine cancer	8.72e-06	8.9e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CYP19A1—uterine cancer	8.72e-06	8.9e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PIK3CA—uterine cancer	7.72e-06	7.88e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTEN—uterine cancer	6.79e-06	6.93e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTEN—uterine cancer	6.75e-06	6.89e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—MTHFR—uterine cancer	6.55e-06	6.69e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—EP300—uterine cancer	6.48e-06	6.61e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—EP300—uterine cancer	6.44e-06	6.57e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AKT1—uterine cancer	6.31e-06	6.44e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTEN—uterine cancer	6.06e-06	6.19e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTEN—uterine cancer	5.92e-06	6.04e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—EP300—uterine cancer	5.78e-06	5.9e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—EP300—uterine cancer	5.64e-06	5.76e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTEN—uterine cancer	5.53e-06	5.64e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—EP300—uterine cancer	5.27e-06	5.38e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PIK3CA—uterine cancer	4.79e-06	4.89e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PIK3CA—uterine cancer	4.76e-06	4.86e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PIK3CA—uterine cancer	4.28e-06	4.36e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PIK3CA—uterine cancer	4.17e-06	4.26e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AKT1—uterine cancer	3.91e-06	3.99e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PIK3CA—uterine cancer	3.9e-06	3.98e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AKT1—uterine cancer	3.89e-06	3.97e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTEN—uterine cancer	3.65e-06	3.72e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AKT1—uterine cancer	3.49e-06	3.57e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—EP300—uterine cancer	3.48e-06	3.55e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AKT1—uterine cancer	3.41e-06	3.48e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKT1—uterine cancer	3.19e-06	3.25e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.57e-06	2.62e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKT1—uterine cancer	2.1e-06	2.14e-05	CbGpPWpGaD
